Six cycles at Mercor, and the structural integrity is holding. In the high-pressure environment of patent-protected synthetics, the external noise can feel like a breach in the hull. There is a lot of speculation lately regarding our integration with Revmed, but my focus remains on the internal architecture. We don't react to market volatility; we patch the leaks and reinforce the foundations. If the pancreatic therapy breakthroughs hold, the value will be in the stability of the compound, not the chatter in the trade corridors. I am grateful to the synthesis team in the Xyloph dome for keeping the pressurized seals tight and the output consistent. We keep fixing, we keep building, and we wait for the next patent filing.